ICONOVO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.7 SEK | +0.23% |
|
-4.40% | -24.68% |
| May. 15 | Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments | CI |
| May. 06 | Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 606.5 | 391.9 | 681.3 | 433.5 | 135.8 | 138.5 | - | - |
| Enterprise Value (EV) 1 | 517.4 | 330.2 | 586.3 | 420.2 | 117.3 | 99.89 | 138.5 | 138.5 |
| P/E ratio | -46.4 x | -22.9 x | -24.4 x | -9.01 x | -2.63 x | -4.35 x | -7.91 x | 87 x |
| Yield | - | - | - | - | - | - | - | 11.5% |
| Capitalization / Revenue | 51.7 x | 22 x | 44.2 x | 25.3 x | 19.2 x | 2.63 x | 1.81 x | 1.1 x |
| EV / Revenue | 44.1 x | 18.6 x | 38.1 x | 24.5 x | 16.6 x | 1.9 x | 1.81 x | 1.1 x |
| EV / EBITDA | -56.3 x | -26 x | -27.7 x | -10.7 x | -3.29 x | -6.62 x | -14.1 x | 6.77 x |
| EV / FCF | -25.8 x | -11.6 x | -15.9 x | -5.28 x | -1.91 x | -2.17 x | -6.59 x | -9.89 x |
| FCF Yield | -3.88% | -8.64% | -6.29% | -18.9% | -52.4% | -46.1% | -15.2% | -10.1% |
| Price to Book | 5.58 x | 4.23 x | 4.97 x | 4.85 x | - | 1.24 x | 0.96 x | 0.95 x |
| Nbr of stocks (in thousands) | 7,776 | 7,776 | 8,848 | 8,848 | 11,756 | 15,918 | - | - |
| Reference price 2 | 78.00 | 50.40 | 77.00 | 49.00 | 11.55 | 8.700 | 8.700 | 8.700 |
| Announcement Date | 2/14/20 | 2/17/21 | 2/18/22 | 2/8/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.74 | 17.79 | 15.41 | 17.12 | 7.078 | 52.65 | 76.4 | 126 |
| EBITDA 1 | -9.193 | -12.72 | -21.16 | -39.27 | -35.69 | -15.1 | -9.85 | 20.45 |
| EBIT 1 | -11.77 | -16.72 | -26.51 | -48.36 | -45.78 | -26.6 | -21.45 | 7.7 |
| Operating Margin | -100.32% | -93.96% | -172.06% | -282.54% | -646.75% | -50.52% | -28.08% | 6.11% |
| Earnings before Tax (EBT) 1 | -11.39 | -17.13 | -26.16 | -48.16 | -45.89 | -21.2 | -25.9 | 13.4 |
| Net income 1 | -11.39 | -17.13 | -26.16 | -48.16 | -45.89 | -21.2 | -25.9 | 13.4 |
| Net margin | -97.04% | -96.3% | -169.78% | -281.4% | -648.4% | -40.27% | -33.9% | 10.63% |
| EPS 2 | -1.680 | -2.200 | -3.150 | -5.440 | -4.390 | -2.000 | -1.100 | 0.1000 |
| Free Cash Flow 1 | -20.09 | -28.54 | -36.91 | -79.61 | -61.43 | -46 | -21 | -14 |
| FCF margin | -171.19% | -160.39% | -239.51% | -465.11% | -867.93% | -87.37% | -27.49% | -11.11% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | 1.000 |
| Announcement Date | 2/14/20 | 2/17/21 | 2/18/22 | 2/8/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.6 | 2.766 | - | - | 0.309 | - | 0.968 | 1.7 | 43.1 | 4.1 | 4.4 |
| EBITDA | -7.231 | - | - | -14.1 | - | - | - | - | - | - | - |
| EBIT 1 | -8.706 | -9.462 | - | -16.59 | -12.88 | - | -9.858 | -9.573 | 24.6 | -17.5 | -18.7 |
| Operating Margin | -241.83% | -342.08% | - | - | -4,169.9% | - | -1,018.39% | -563.12% | 57.08% | -426.83% | -425% |
| Earnings before Tax (EBT) | - | -9.258 | - | -16.64 | -13.04 | - | - | - | - | - | - |
| Net income | -8.655 | -9.258 | -10.06 | -16.64 | -13.04 | -9.971 | - | - | - | - | - |
| Net margin | -240.42% | -334.71% | - | - | -4,219.74% | - | - | - | - | - | - |
| EPS | - | - | -1.140 | -1.880 | - | -0.9700 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/18/22 | 4/29/22 | 10/28/22 | 2/8/23 | 4/28/23 | 10/27/23 | 2/15/24 | 4/25/24 | - | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 89.2 | 61.7 | 94.9 | 13.3 | 18.5 | 38.6 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -20.1 | -28.5 | -36.9 | -79.6 | -61.4 | -46 | -21 | -14 |
| ROE (net income / shareholders' equity) | -13.2% | -17% | -22.8% | -42.6% | -45.3% | - | -19% | 1.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 14.00 | 11.90 | 15.50 | 10.10 | - | 7.000 | 9.100 | 9.200 |
| Cash Flow per Share | -1.550 | -2.050 | -1.320 | -4.820 | - | - | - | - |
| Capex 1 | - | 12.6 | 25.9 | 36.9 | 0.71 | 16 | 14 | 12 |
| Capex / Sales | - | 70.68% | 168.04% | 215.85% | 10.06% | 30.39% | 18.32% | 9.52% |
| Announcement Date | 2/14/20 | 2/17/21 | 2/18/22 | 2/8/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.68% | 13.1M | |
| +10.16% | 28.08B | |
| +25.93% | 2.46B | |
| +23.80% | 2.43B | |
| -48.88% | 2.23B | |
| +33.33% | 2.02B | |
| -32.64% | 1.98B | |
| -23.53% | 1.58B | |
| +10.42% | 1.35B | |
| +34.05% | 1.33B |
- Stock Market
- Equities
- ICO Stock
- Financials Iconovo AB
